Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09KTS
|
||||
| Former ID |
DNCL002550
|
||||
| Drug Name |
Ibrutinib
|
||||
| Synonyms |
PCI-32765; Ibrutinib (BTK inhibitor)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Janssen Biotech; Pharmacyclics
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H24N6O2
|
||||
| InChI |
InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
|
||||
| InChIKey |
XYFPWWZEPKGCCK-GOSISDBHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
49837088, 57132050, 123051065, 124898784, 124898785, 136940589, 136961336, 137472671, 152258295, 160647134, 162202692, 163312254, 163679284, 164045821, 164193915, 165245631, 171572071, 172919350, 174007139, 175267389, 176250273, 178103494, 184611713, 184816969, 189025882, 198993428, 215784879, 223375297, 223485070, 223600477, 223685684, 223704724, 224184328, 226558356, 242585660, 247523488, 249736825, 251971042, 252088605, 252110183, 252160516, 252215999, 252451849
|
||||
| Drug Resistance Mutation (DRM) | |||||
| DRM | DRM Info | ||||
| Target and Pathway | |||||
| Target(s) | Tyrosine-protein kinase BTK | Target Info | Inhibitor | [543527] | |
| PANTHER Pathway | B cell activation | ||||
| PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
| Reactome | MyD88:Mal cascade initiated on plasma membrane | ||||
| Regulation of actin dynamics for phagocytic cup formation | |||||
| DAP12 signaling | |||||
| FCERI mediated Ca+2 mobilization | |||||
| MyD88 deficiency (TLR2/4) | |||||
| IRAK4 deficiency (TLR2/4) | |||||
| RHO GTPases Activate WASPs and WAVEs | |||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| References | |||||
| Ref 524263 | ClinicalTrials.gov (NCT01833039) An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma. U.S. National Institutes of Health. | ||||
| Ref 541962 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912). | ||||
| Ref 551043 | Janssen's IMBRUVICA (ibrutinib) Receives Additional European Commission Approval for the Treatment of Waldenstrom's Macroglobulinemia. Janssen-Cilag International NV (Janssen). Jul 10, 2015. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.